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Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are a relatively newer class of anti-
hyperglycemic medications that reduce blood glucose by inhibition of renal glucose re-uptake, 
thereby increasing urinary glucose excretion. Although glycosuria is the primary mechanism 
of action of these agents, there is some evidence suggesting they can reduce insulin resistance 
and induce peripheral insulin sensitivity. Identifying the molecular mechanisms by which these 
medications improve glucose homeostasis can help us to develop newer forms of SGLT2i with 
lesser side effects. We have reviewed the molecular mechanisms and signaling pathways by 
which SGLT2i therapy improve insulin sensitivity and ameliorates insulin resistance.  
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The global prevalence of diabetes mellitus (DM) is rising rapidly [1]. This chronic disorder 
results in the development of various debilitating complications as well as deaths worldwide 
[2]. Chronic hyperglycemia seen in DM can induce various pathophysiologic pathways 
involved in tissue dysfunction such as oxidative stress, inflammation, apoptosis, fibrosis, 
hyperexpression of growth factors and hemodynamic variations [3]. Various medications have 
been developed to normalize hyperglycemia and thereby preventing diabetic complications [4, 
5].  
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are a newly developed class of agents 
that reduce hyperglycemia in DM by inhibition of renal glucose re-uptake and thereby 
increasing the excretion of glucose in the urine [5, 6]. These agents act primarily by inducing 
glycosuria but there is some evidence that they can also induce insulin sensitivity in peripheral 
tissues [7, 8]. SGLT2i is also associated with some side effects in patients with DM [9-14]. In 
this review, we have discussed various molecular pathways involved in the modulation of 
insulin sensitivity by SGLT2i.     
Type 2 diabetes (T2DM) is the most prevalent type of diabetes which account for about 90-
95% of patients with diabetes and is linked mainly to inadequate response to insulin (decreased 
insulin sensitivity) and insulin resistance in the peripheral tissues [15-17]. T2DM is a disorder 
of glucose homeostasis. Glucose is the most abundant monosaccharide in circulation and the 
preferred substrate for many types of cells in the human body [18, 19]. This carbohydrate exists 
mainly as a polysaccharide in starch and then converted by catabolic and enzymatic processes 
to a hexose monosaccharide  [18, 19]. This monosaccharide is a hydrophilic molecule with a 
molecular weight of 180.156 g/mol,  which is too large to pass easily across the cell membrane, 
thereby needing a specific carrier [19]. Glucose has two major ways for entering into the cells: 
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(1) via active mechanism by SGLTs and (2) via specific carriers (independent of sodium) [19]. 
The function of SGLTs is the sections below [20]. Glucose carriers (GLUT) are a family of 
proteins that provide bidirectional facilitated glucose transport across the cellular plasma 
membrane [19, 21]. These carriers work without consuming energy and are based on the 
glucose concentration gradient across the cell membrane. There are at least 14 known GLUT 
members in human [19, 22]. However, GLUT-1, GLUT-2, GLUT-3 and GLUT-4 are more 
critical in glucose homeostasis [19]. While GLUT-1 and GLUT-3 are widely expressed, high-
affinity and low-capacity transporters, GLUT-2 is high-affinity and low capacity which is 
expressed in pancreatic beta cells, liver and basolateral side of intestinal and renal tubular cells 
[19].  
Glucose is phosphorylated to glucose-6-phosphate within the beta cells by glucokinase enzyme 
[23]. This enzyme acts as "glucose sensor" which controls the rate of glucose entering into the 
islets and in turn controls the rate of insulin secretion [23]. ATP (adenosine triphosphate) 
synthesis by G6P in beta cells raises the ATP to ADP (adenosine diphosphate) ratio which in 
turns closes ATP-sensitive K+ channels (sensitive to sulfonylureas), depolarizes beta cell 
membrane and increases intracellular calcium concentration by opening the voltage-dependent 
Ca2+ channels in beta cells [23]. Rising the levels of intracellular Ca2+ stimulates the exocytosis 
of secretory granules containing insulin/proinsulin from the beta cells into the circulation [23].              
Insulin  signal transduction  
Insulin signal transduction (IST) or insulin signaling pathway is initiated by  insulin binding to 
the α-subunit of specific receptors known as insulin receptors (IRs), a member of 
transmembrane tyrosine kinases composed of α and β  subunits, which are activated by insulin 
as well as IGF1 1 and 2 [24]. This binding induces structural changes in the β  subunit by 
prompting auto-phosphorylation in tyrosine residues followed by downstream events such as 
                                                           
1 Insulin-like growth factor  
5 
 
recruitment of different adaptor proteins i.e. insulin receptor substrates (IRSs), Shc2 protein, 
and APS protein3 [19, 25]. These processes provide an appropriate binding site for the IRS-14 
[25]. Several types of insulin-dependent kinases such as ERK1/25, atypical PKC6, S6K17, 
SIK28, AKT, mTOR9, and ROCK110 and other types of  kinases including AMPK11 and 
GSK312 can phosphorylate IRSs to activate them [25, 26]. Activated IRS-1 links to PI3K13 and 
activates it and catalyzes the conversion of PIP2 14 to PIP3 15 [27]. PIP3 itself is a potent activator 
for PKB (protein kinase B also known as Akt), which in turn, facilitates glucose entering into 
the cells by localization of GLUT-4 and inhibits glycogen synthase kinase leading to more 
glycogen synthesis [27, 28]. The insulin sensitivity can be modulated in all these steps of 
insulin signal transduction pathways [29-31].  
SGLT2 Inhibitors  
Sodium-glucose co-transporters (SGLT) are two distinct forms of active cotransporters (as type 
1 and 2) that mainly localized in the brush border of S2 and S3 segments of proximal renal 
tubules (as well as in intestines) which reabsorb the filtrated urinary glucose and to prevent 
glucose excretion [32]. SGLT2 inhibitors (SGLT2i) are a class of medications which 
specifically inhibit these active carriers and thereby induce urinary glucose excretion leading 
to lower levels of glycemia in patients with diabetes [5]. This potent oral glucose lowering 
                                                           
2 SHC-transforming  
3 adapter protein with a PH and SH2 domain  
4 insulin receptor substrate type 1  
5 extracellular signal‐regulated kinase 1/2  
6 protein kinase C 
7 Ribosomal protein S6 kinase beta-1  
8 serine/threonine-protein kinase 2 
9 mammalian target of rapamycin  
10 Rho-associated protein kinase 1  
11 AMP-activated protein kinase  
12 Glycogen synthase kinase 3  
13 phosphoinositide 3-kinase 
14 Phosphatidylinositol 4,5-bisphosphate  
15 Phosphatidylinositol 3,4,5-trisphosphate  
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agents work entirely independent of insulin and are dependent on blood glucose levels so that 
they have a lower risk of hypoglycemia [33].  
 
Since the discovery of phlorizin as the first SGLT2i in the early of 1980s, several forms of 
these agents have introduced which all reduce the blood glucose below the threshold of tubular 
transporter for glucose reabsorption [9, 33-35]. However, in addition to its anti-hyperglycemic 
effects through glycosuria, they may provide other beneficial effects such as suppression of 
gluconeogenesis, improving insulin sensitivity in peripheral tissues, increasing glucagon 
response and stimulation of insulin secretion from the beta cells of pancreatic islets [8, 36-38]. 
Canagliflozin, dapagliflozin, and empagliflozin are the known forms of this class of 
antidiabetic drugs [39]. The side effects of  SGLT2i include dehydration, dizziness, 
hypotension and genito-urinary infections [39].   
GLT2i and iinsulin sensitivity 
Emerging evidence indicates that SGLT2 inhibition can interfere with various steps of IST and 
modulate insulin sensitivity in peripheral tissues [7, 8, 36]. In the following sections, we present 
the main involved molecular mechanisms (Table 1).  
1. Inhibition of glucose toxicity 
SGLT2i promotes excretion of glucose through urine, thereby lowering blood glucose and 
glucotoxicity [9]. Chronic hyperglycemia results in glucotoxicity as seen in the diabetic milieu 
[40-42]. This toxic milieu negatively affects beta-cell function and is closely related to insulin 
resistance [43]. On the other hand, strong evidence suggests that SGLT2i-induced glycosuria 
potentially improves glucotoxicity [44].  
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Mervoric et al. in 2014 has shown that SGLT2 inhibition by dapagliflozin reduces glucotoxicity 
and thereby improves glycemic control in the diabetic milieu [7]. Two weeks of dapagliflozin 
therapy in men with diabetes improved glucotoxicity by lowering the fasting blood glucose and 
increasing tissue sensitivity to insulin [7]. These anti-glucotoxicity effects of SGLT2i are 
reversible after treatment cessation [7]. List and coworkers in 2011 provided further evidence 
suggesting that SGLT2i therapy induces insulin sensitivity, beta-cell activity and morphology 
preservation via ameliorating the glucotoxicity [43]. Kern and colleagues emphasized this 
finding in 2016, where they found that SGLT2i therapy in diabetic mice improved insulin 
signaling, leading to better glucose homeostasis [8]. These reports suggest that attenuation of 
toxic effects of glucose by SGLT2i is one of the main molecular pathways in which they can 
improve insulin sensitivity [7, 8, 43].     
   
2. Caloric disposition and weight loss  
Caloric disposition is an established effect of SGLT2i therapy since they promote urinary 
glucose excretion [45]. Caloric disposition can translate to weight loss as well as a reduction 
in the circulating lipids [45-47]. It has been demonstrated that SGLT2i therapy can reduce body 
weight in patients with diabetes [48]. On the other hand, it has been well confirmed that lower 
mass of adipose tissue and lower levels of circulating lipids are correlated to an increase in 
insulin sensitivity [49]. The role of inflammatory responses in insulin resistance is completely 
verified and patients with diabetes have relatively higher levels of circulatory inflammatory 
mediators [50, 51]. The central part of these inflammatory responses is mediated by adipocytes 
and their related active mediators, known as adipokines [50]. These active biologic adipocyte-
derived cytokines have prominent roles in insulin resistance [52]. There are strong animal and 
human evidence indicating that high-fat diet and obesity are one of the main underlying causes 
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of insulin resistance and the onset of DM [53, 54] which SGLT2i therapy can potentially 
reverse [55]. For example, Shamansurova et al. in 2016, on a diabetic mouse, demonstrated 
that depletion of adipose tissue improved insulin sensitivity by improving locomotor activity 
and basal metabolism. Furthermore, increasing adiponectin which is another form of 
adipocytokines, is associated with insulin sensitivity [56]. Since lesser adipocytes can 
potentially improve insulin sensitivity, weight loss is strongly recommended in patients with 
T2DM [56].   
Xu et al. in 2018 demonstrated that "visceral fat lowering" effect of SGLT2i can markedly 
improve the insulin sensitivity by ameliorating the lipotoxicity [57]. They reported that SGLT2i 
therapy in patients with diabetes could attenuate insulin resistance by lowering the rate of 
adipocyte-induced inflammatory responses by regulating energy homeostasis and a reduction 
in lipotoxicity-induced insulin resistance [57]. Empagliflozin (SGLT2i) increases insulin 
sensitivity by ameliorating inflammatory processes and visceral fat lowering via an M2 
macrophage polarization-dependent mechanism in white adipose tissue (WAT) of diabetic 
mice. Also, it promoted browning adipose tissue led to increased energy expenditure and 
thermogenesis[58]. Xu and colleagues provided evidence for the effects of SGLT2i on WAT 
browning and fat utilization induced by activating M2 macrophage. Thus, they concluded that 
empagliflozin has beneficial effects on obesity-related inflammation and insulin resistance.  
[57]. In a clinical trial with 38 diabetic patients, SGLT2i therapy by canagliflozin significantly 
improved insulin resistance by a reduction in body weight as well as lowering visceral and 
ectopic fatty tissues in Japanese patients with T2DM [59]. Furthermore, Singh and coworkers 
in 2019 provided the same evidence about Indian patients with T2DM suggesting that visceral 
fat lowering effect of SGLT2i therapy potentially improves insulin sensitivity [60]. Okamoto 
et al. in 2016 found that dapagliflozin improved adipocyte function which increased 
adiponectin in obese patients with T2DM [61]. Matsumura and coworkers in 2017 also reported 
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that canagliflozin increased adiponectin-induced glucose homeostasis in patients with T2DM 
[62]. Tobita et al in 2017 demonstrated that canagliflozin therapy in patients with T2DM 
improved glucose metabolism by reducing visceral fat resulting in metabolic improvement 
[63]. Garvey et al. in 2018 provided more evidence implying that canagliflozin improved 
glucose homeostasis by improving lipid metabolism and leptin level in patients with diabetes 
[64]. This evidence strongly suggests that SGLT2i therapy can increase insulin sensitivity and 
improve glucose homeostasis at least partly via lowering adipocytes number, fatty tissues and 
plasma lipids [57, 59, 60].       
3. Attenuating the inflammatory responses  
Inflammatory responses are potent upstream events in the pathophysiology of DM, 
contributing to insulin resistance and lowering insulin sensitivity in the peripheral tissues [52]. 
Patients with diabetes have higher levels of inflammatory mediators, including active cytokines 
in the blood, which potentially impair IST, thereby reducing insulin sensitivity [52]. 
Inflammation hypothesis states that inflammation is strongly involved in the pathophysiology 
of DM [65, 66]. There is growing evidence that SGLT2i can inhibit or decline inflammatory 
processes and prevent the expression of inflammatory mediators [67, 68]. It has been suggested 
that SGLT2 inhibitors can suppress inflammatory responses via both direct (impact on the 
immune system) and indirect molecular pathways via at least 5 different molecular mechanisms 
such as modulation of the renin-angiotensin system (RAS), altering hemodynamic changes, 
reduction in obesity‐induced inflammation, modulation of immune system function and 
readjustment of the redox state in tissue leading to a lower rate of inflammatory responses [57, 
69-74]. Since lower inflammatory response can be translated to a reduced impairment in IST 
and lower risk for insulin resistance, we concluded that anti-inflammatory properties of 
SGLT2i could be exploited to design novel therapeutic approaches for patients with diabetes.  
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4. Improvement in beta-cell function  
Majority of patients with T2DM have some impairment in pancreatic beta-cell function [75, 
76]. They have dysfunctional islets with suboptimal response to stimuli and thereby, inadequate 
insulin release [76]. The number of functional beta cells is also reduced due to 
pathophysiological mechanisms such as oxidative damage, fibrosis and inflammation leading 
to higher rates of apoptotic processes [76, 77]. Improving beta cells function is one of the main 
targets in patients with diabetes to normalize hyperglycemia [78, 79]. Although one may 
conclude that SGLT-2i can only increase insulin action, there direct evidences suggesting 
SGLT2 inhibition increases insulin sensitivity by improving islet cell function in diabetic 
milieu [55, 80-82]. This action could be possibly through improvement in beta cell-mediated 
insulin dependent glucose homeostasis.    
Jurczak et al. in 2013 demonstrated that SGLT2 deletion in animals with diabetes improves 
glucose homeostasis and enhances insulin sensitivity by preserving the beta cells function in a 
diabetic milieu [55]. They have observed a 60% increase in beta cell mass and lower levels of 
apoptotic death leading to more functional pancreatic islets in SGLT2 knockout diabetic mice 
[55]. Kaneto and colleagues in 2017 observed that SGLT2i therapy protects beta cells against 
glucose toxicity and β-cell lipotoxicity as well as improves islet cell function leading to 
increased insulin sensitivity [80]. SGLT2 inhibitory agents can preserve islet function by 
attenuating the pathophysiologic pathways and deleterious molecular mechanisms [80]. They 
can suppress glucotoxicity, lipotoxicity, inflammatory processes, fibrotic processes and 
oxidative damages leading to lower rates of beta cell death and more functional mass of islets 
thereby improving insulin sensitivity and glucose homeostasis [79-81, 83]. Cheng et al. in 2016 
surveyed the potential beneficial effects of empagliflozin and found that it improved glucose 
homeostasis by preserving the beta-cell function probably via suppressing the glucotoxicity-
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induced oxidative stress-dependent beta-cell death and by increasing regeneration of pancreatic 
islet cells in diabetic mice [83]. Also, Asahara et al. in 2019 suggested that SGLT2i re-adjust 
glucose homeostasis by preserving beta cells function [81].  
Merovci et al. in 2015 in a human clinical trial demonstrated that SGLT2i with dapagliflozin 
increased insulin sensitivity by an improvement of beta cells function in T2DM individuals 
[84]. Al Jobori et al. in 2018 reported that empagliflozin therapy for two weeks is associated 
with better beta-cell function in patients with diabetes [82]. They showed that empagliflozin 
therapy increased islets' glucose sensitivity during periods of hyperglycemic clamps which is 
a method for assessing the function of beta cells [82]. Moreover, Takahara and coworkers in 
2015 evaluated the islets function using disposition index and found that four weeks of 
treatment with ipragliflozin improved beta-cell function in patients with T2DM [85]. These 
strong experimental and human evidence firmly suggest that SGLT2i therapy improves beta 
cell function in a diabetic milieu [81-83, 85]. They demonstrated that SGLT2i therapy in 
diabetic milieu is a potential way for improvement of beta-cell function via several mechanisms 
leading to an increased number of functional beta-cells and thereby more ability to secrete 
insulin in response to circulating glucose [81-83, 85].                 
 
5. Reduction in oxidative stress  
Free radical generation is a common phenomenon in the biologic milieu which has important 
biologic functions such as cellular signaling in the physiologic range [86]. In high 
concentrations, free radical species produces oxidative stress which is one of the main and 
potent upstream events in various pathophysiologic states including DM [87]. Oxidative stress 
impairs IST significantly and reduces insulin sensitivity, thereby increasing insulin resistance 
leading to DM [88, 89]. It negatively affects peripheral insulin sensitivity and down-regulates 
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glucose transport system in insulin-dependent cells [88]. Alleviating the free radical production 
and normalizing its concentration near to the physiologic ranges is one of the main therapeutic 
targets in DM and preventing its complications [90, 91]. 
There is growing evidence that SGLT2i improve redox state in the diabetic milieu [92]. They 
can exert potent antioxidative properties by several molecular mechanisms including 
improvement in mitochondrial dysfunction [92, 93], regulating the RAS (renin-angiotensin 
system) activity [70, 94], attenuating inflammation-induced free radical generation [95, 96], 
lowering the AGEs (advanced glycation end products) and AGE/RAGE (receptors for 
advanced glycation end products) crosstalk [97, 98], down-regulating the pro-oxidant enzymes 
expression/activity as NADPH (Nicotinamide adenine dinucleotide phosphate) oxidase, eNOS 
(endothelial nitric oxide synthase) and xanthine oxidase [99, 100]. Based on this evidence, 
SGLT2 inhibition ameliorates oxidative stress and could improve insulin sensitivity by 
attenuating oxidative damages in the diabetic milieu [57, 101].               
  
 







Sodium-glucose co-transporter inhibitors are a relatively new class of medications used in the 
management of diabetes for lowering blood glucose as well as reducing microvascular and 
macrovascular complications associated with it. Beyond the glycosuric effects, these agents 
have pleiotropic effects on glucose homeostasis (Table 1). While they are considered as potent 
glucose-lowering drugs, they can also improve insulin sensitivity and glucose homeostasis via 
several molecular pathways including reduction of glucotoxicity and lipotoxicity, improvement 
in beta cell function, reduction of oxidative damages and inflammatory processes as well as 
induction of caloric disposition and weight loss (Fig 1).  
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Table 1.  Main molecular mechanisms by which SGLT2i therapy increase insulin 
sensitivity (IST=insulin signal transduction)  
Molecular 
Mechanisms  Detailed Effects of SGLT2i  Ref.  
Inhibition of Glucose 
Toxicity 
Normalize hyperglycemia near to physiologic ranges 
leading to lowering rates of glucotoxicity and thereby 
increasing peripheral insulin sensitivity  
[7, 8, 43]  
Caloric Disposition and 
Weight Loss 
Induce caloric deposition by glycosuria leading to lesser 
adipocytes number as well as lesser adipocytokines and 
lipotoxicity thereby improving peripheral insulin 
sensitivity   
[57, 59, 60]  
Attenuating the 
Inflammatory Responses 
Induce peripheral insulin sensitivity by reduction of 
various inflammatory processes  
[58, 68, 70, 
102-106] 
Improvement in Beta 
Cell Function 
Improve beta cell mass/function by ameliorating the 
pathophysiological pathways involved in the islets cells' 
death  
[55, 79-85] 
Reducing the Oxidative 
Stress 
Reduce insulin resistance by attenuating the oxidative 
stress-dependent IST impairment  
[57, 70, 89, 94, 
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